Kiniksa Pharmaceuticals Reports Strong Earnings and Raises Sales Guidance
Kiniksa Pharmaceuticals (KNSA) saw its stock rise nearly 24% after reporting strong first-quarter 2026 earnings, with revenue and net income exceeding analyst estimates. The company's drug Arcalyst, now approved for pericarditis, drove the growth, leading management to raise its net sales guidance for the year.
Tickers: $KNSA
Topics: Arcalyst Biotech Earnings Beat Kiniksa Pharmaceuticals Revenue Growth Stock Performance